ATE353645T1 - Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia - Google Patents

Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia

Info

Publication number
ATE353645T1
ATE353645T1 AT02774687T AT02774687T ATE353645T1 AT E353645 T1 ATE353645 T1 AT E353645T1 AT 02774687 T AT02774687 T AT 02774687T AT 02774687 T AT02774687 T AT 02774687T AT E353645 T1 ATE353645 T1 AT E353645T1
Authority
AT
Austria
Prior art keywords
oxo
dyskinesia
producing
treatment
pyrrolidine derivatives
Prior art date
Application number
AT02774687T
Other languages
English (en)
Inventor
Renee Grimee
Henrik Klitgaard
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Application granted granted Critical
Publication of ATE353645T1 publication Critical patent/ATE353645T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02774687T 2001-10-08 2002-10-07 Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia ATE353645T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01123976 2001-10-08

Publications (1)

Publication Number Publication Date
ATE353645T1 true ATE353645T1 (de) 2007-03-15

Family

ID=8178883

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02774687T ATE353645T1 (de) 2001-10-08 2002-10-07 Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia

Country Status (12)

Country Link
US (2) US20040242671A1 (de)
EP (1) EP1435943B1 (de)
JP (1) JP4351909B2 (de)
AT (1) ATE353645T1 (de)
AU (1) AU2002340971B2 (de)
CA (1) CA2461961A1 (de)
DE (1) DE60218193T2 (de)
ES (1) ES2281545T3 (de)
HU (1) HUP0401667A2 (de)
MX (1) MXPA04002714A (de)
PL (1) PL370529A1 (de)
WO (1) WO2003030899A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7338975B2 (en) 2003-02-12 2008-03-04 Bristol-Myers Squibb Co. Lactams as modulators of chemokine receptor activity
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
US20110212944A1 (en) * 2008-07-01 2011-09-01 Julie Liu 2-oxo-1-pyrrolidine derivatives
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
WO2012027825A1 (en) * 2010-08-31 2012-03-08 Mcmaster University Method of treating dopamine-related neuropsychiatric disorders
MX2016007259A (es) 2013-12-03 2016-08-04 Du Pont Pirrolidinonas como herbicidas.
US11589583B2 (en) 2013-12-03 2023-02-28 Fmc Corporation Pyrrolidinones herbicides
US9944602B2 (en) 2014-07-02 2018-04-17 E. I. Du Pont De Nemours And Company Piperidinone herbicides
EP3230264B1 (de) 2014-12-08 2019-09-11 FMC Corporation 3-oxo-3-(arylamino)-propanoate, verfahren zu deren herstellung und deren verwendung zur herstellung von pyrrolidinonen
EP3280709B1 (de) 2015-04-10 2021-05-26 FMC Corporation Substituierte cyclische amide als herbizide
CN107531658B (zh) 2015-04-27 2021-07-27 Fmc公司 作为除草剂的丁内酯
PL3294743T3 (pl) 2015-05-12 2020-03-31 Fmc Corporation Podstawione arylem związki bicykliczne jako środki chwastobójcze
WO2016196019A1 (en) 2015-05-29 2016-12-08 E I Du Pont De Nemours And Company Substituted cyclic amides as herbicides
CN107709310B (zh) 2015-06-02 2021-09-24 Fmc公司 取代的环酰胺及其作为除草剂的用途
CN108137512B (zh) 2015-07-31 2022-05-31 Fmc公司 用作除草剂的环状n-酰胺化合物
CA3047724A1 (en) 2016-12-21 2018-06-28 Fmc Corporation Nitrone herbicides
WO2018175231A1 (en) 2017-03-21 2018-09-27 Fmc Corporation Herbicidal mixture, composition and method
CA3057297A1 (en) 2017-03-21 2018-09-27 Fmc Corporation Pyrrolidinones and a process to prepare them
AR111839A1 (es) 2017-05-30 2019-08-21 Fmc Corp Lactamas 3-sustituidas herbicidas
AR111967A1 (es) 2017-05-30 2019-09-04 Fmc Corp Amidas herbicidas
GB201901559D0 (en) 2019-02-05 2019-03-27 Syngenta Crop Protection Ag Herbicidal compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1309692A (en) * 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
AR026610A1 (es) * 1999-12-01 2003-02-19 Ucb Sa Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders

Also Published As

Publication number Publication date
JP2005504834A (ja) 2005-02-17
AU2002340971B2 (en) 2007-04-26
WO2003030899A3 (en) 2004-01-08
ES2281545T3 (es) 2007-10-01
EP1435943B1 (de) 2007-02-14
PL370529A1 (en) 2005-05-30
US20080167366A1 (en) 2008-07-10
MXPA04002714A (es) 2004-07-05
DE60218193T2 (de) 2007-11-22
WO2003030899A2 (en) 2003-04-17
DE60218193D1 (de) 2007-03-29
EP1435943A2 (de) 2004-07-14
HUP0401667A2 (hu) 2004-12-28
CA2461961A1 (en) 2003-04-17
JP4351909B2 (ja) 2009-10-28
US20040242671A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
ATE353645T1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE268179T1 (de) Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung
CY1115484T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
ATE213164T1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
IL189546A0 (en) Therapy for the treatment of disease
SG166125A1 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimeræs disease
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
ATE402710T1 (de) Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen
TW200509933A (en) Therapeutic agents
DE60320579D1 (de) Mucuna pruriens und extrakte daraus zur behandlung von neurologischen erkrankungen
WO2005062992A3 (en) Substituted melatonin derivatives, process for their preparation, and methods of use
ATE311866T1 (de) Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln zur behandlung von erkrankungen rheumatischer natur
IT1306184B1 (it) Nitrilossi derivati della (r) e (s)-carnitina.
ATE492285T1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties